Bamlanivimab Implementation Panel

Bamlanivimab is authorized (with terms and conditions) by Health Canada to treat adult and pediatric patients 12 years of age or older with mild to moderate COVID-19, who weigh at least 40 kg and are at high risk of progressing to severe COVID-19 illness and/or hospitalization. The drug is administered intravenously.

CADTH is convening an implementation panel of interdisciplinary clinical specialists with experience in the treatment of patients with symptoms of COVID-19 to help determine criteria for the use of bamlanivimab.

The panel’s objective is to provide advice on which patients are most likely to benefit from treatment with this drug and parameters for monitoring patients following intravenous transfusion. This work is being undertaken to support pandemic preparedness, where evidence-informed criteria may be useful to support decision-making.

To inform panel discussions, CADTH completed a Technology Review to appraise the evidence on bamlanivimab from the BLAZE-1 trial.

To further inform decision-makers about developments in this therapeutic area, a Horizon Scan on virus-neutralizing monoclonal antibodies against SARS-CoV-2 is currently in development and will be published in December 2020.

Link to Report:

Bamlanivimab (LY-CoV555) in the Treatment of Outpatients With COVID-19: A Critical Appraisal of an Interim Analysis of the BLAZE-1 Trial